Fuji Pharma News

Volume change rate ranking (14:00) ~ XEBIO HD, YE DIGITAL, etc. are ranked

* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [5/22 14:32 as of] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate Stock Price Change Rate ＜8281＞ XEBIO HD 1401400 106827.2 286.13% 0.10

Fisco JapanMay 22 01:51 ET

Volume change rate ranking (around 9 o'clock) ~ Headwater, Yamazaki, etc. are ranked

* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [5/21 9:32 as of 9:32] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate Stock Price Change Rate ＜2517＞ MXSJRE Core 13270 107185.08 244.33% -0.002

Fisco JapanMay 21 20:40 ET

Fuji Pharma: Confirmation

EDINETMay 10 01:27 ET · Announcements

Fuji Pharma: Quarterly Report - 60th Term 2nd Quarter (2024/01/01 - 2024/03/31)

EDINETMay 10 01:27 ET · Announcements

Fuji Pharma: Notice regarding differences between the second quarter earnings forecast and actual results and partial revisions to the full-year earnings forecast

JPXMay 9 04:00 ET · Announcements

Fuji Pharma: Summary of Financial Results for the 2nd Quarter Ending 2024/9 [Japanese GAAP] (Consolidated)

JPXMay 9 04:00 ET · Announcements

Fuji Pharma Sees 1H Parent Pretax Y2.17B

PARENT New Forecast Prior For Year to Mar 2024 Forecast Revenue Y21.34 bln N/A Pretax Profit Y2.17 bln N/A Net Prof

Dow JonesMay 9 04:00 ET

Kirin HD, Takeda Pharmaceutical, Sumitomo, SoftBank (9th)

*The above calendar is just a schedule and is subject to change due to company circumstances. ---------------------------------------5/9 (Thu) ＜1375＞Snow Country Maitake ＜1720＞Tokyu Construction＜1738＞Nittoh ＜1764＞Kudo Construction＜1788＞Santo Kogyo ＜1799＞Daiichi Kenset＜1869＞Meikouken ＜1870＞Yahagi Kenset＜1929

Fisco JapanMay 8 17:30 ET

Convertible Stock List (Part 2) [Parabolic Signal Convertible Stock List]

○List of trading stocks market code stock name closing price SAR Tokyo Stock Exchange Prime ＜4369＞ Tri Chemical 4435 3880 ＜4452＞ Kao 6525 6322 ＜4462＞ Ishihara Chemical 1780 1669 ＜4471＞ Sanyo Kasei 4135 4035 ＜4481＞ base 　 　 　 　 　

Fisco JapanApr 30 19:40 ET

Fudo Tetra, Aida Engineering, etc.

＜1813＞Fudo Tetra & Fissimo Capital Management Co., Ltd. (EFFISSIMO CAPITAL MANAGEMENT PT. Ltd.) Stock Ownership Ratio 18.04% → 19.13% Reporting Obligation Date 2024/04/18 ＜4373＞Simplex Holdings Co., Ltd. Kaneko Hideki Stock Holding Ratio 18.47% → 18.44% Reporting Obligation

Fisco JapanApr 25 19:48 ET

LaSalle Logi, Fujitec, etc. (added) Rating

Upgrade-Bullish Code | Stock Name | Securities Company | Conventional | After Change |------|---------|---------|<3466＞|LaSalle Logi | Mizuho | “Neutral” | “Buy” |＜5332＞|TOTO | Mizuho | “Neutral” | “Neutral” | “Buy” |＜5938＞|LIXIL |GS

Fisco JapanApr 18 23:23 ET

Fuji Pharma Sees 1H Net Y4.14B

Fuji Pharma Co. Ltd. also released the following forecasts: GROUP 1st Half To Mar 2024 Revenue Y23.67 bln Operating Profit Y2.05 bln Pretax Profi

Dow JonesFeb 8 03:00 ET

Fuji Pharma Keeps FY Parent Pretax View at Y5.23B

PARENT New Forecast Prior For Year to Sep 2024 Forecast Revenue Y45.02 bln Y45.02 bln Operating Profit Y4.54 bln

Dow JonesDec 13, 2023 01:44 ET

Fuji Pharma Sees FY Net Y4.02B

Fuji Pharma Co. Ltd. also released the following forecasts: GROUP 1st Half To Year Ending Mar 2024 Sep 2024 Revenue Y23.67 bln Y48.93 bln O

Dow JonesNov 9, 2023 03:00 ET

Mithra to Receive EUR 2.5 Million Milestone Payment From Fuji Pharma Under ESTELLE Licensing Agreement

Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE licensing agreement Relates to the submission of a marketing approval application in JapanMarks strong progress in 2016

GlobeNewswireOct 23, 2023 01:00 ET

Alvotech Gains Ground in Japan as Partner Fuji Pharma Secures Approval for Stelara Biosimilar

Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in J

BenzingaSep 25, 2023 04:03 ET

Vistagen Therapeutics, Fuji Pharma Sign Exclusive Negotiation Deal for Japanese Market

Vistagen Therapeutics (VTGN) and Fuji Pharma said Tuesday they have signed an 18-month exclusive negotiation deal for a potential development and commercialization license for Vistagen's PH80 in Japan

MT NewswiresSep 5, 2023 10:05 ET

Fuji Pharma Sees FY Net Y2.97B

Fuji Pharma Co. Ltd. also released the following forecasts: GROUP Year Ending Sep 2023 Revenue Y43.31 bln Operating Profit Y4.05 bln Pretax Profi

Dow JonesAug 8, 2023 04:00 ET

Mithra Receives EUR 1.25 Million Milestone Payment From Fuji Pharma Under Estelle Licensing Agreement

Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma under EstelleLicensing Agreement Relates to completion of the interim clinical study reports of Phase 3 trials in patients with dysm

GlobeNewswireAug 3, 2023 01:30 ET

Fuji Pharma 1H Net Y1.77B Vs Net Y1.83B

Fuji Pharma Co. Ltd. (4554.TO) Japan 1st Half Ended March 31 GROUP 2023 2022 Revenue Y19.23 bln Y17.73 bln Operating Profit Y1.82 bln Y2

Dow JonesMay 11, 2023 04:00 ET